Technical Analysis for BGNE - BeiGene, Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical BGNE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | -5.93% | |
| Inside Day | Range Contraction | -5.93% | |
| Slingshot Bearish | Bearish Swing Setup | -7.33% | |
| Crossed Above 200 DMA | Bullish | -7.33% | |
| Cup with Handle | Other | -7.33% | |
| Outside Day | Range Expansion | -7.33% | |
| Fell Below 200 DMA | Bearish | -2.77% | |
| Stochastic Reached Oversold | Weakness | -2.77% | |
| Down 3 Days in a Row | Weakness | -2.77% | |
| Down 4 Days in a Row | Weakness | -2.77% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Gap Down Partially Closed | 12 minutes ago |
| Gapped Down (Full) | 12 minutes ago |
| Down 3% | 12 minutes ago |
| Down 2 % | 12 minutes ago |
| Down 1% | 12 minutes ago |
Free Daily (Stock) Chart Reading
- Earnings date: 09/27/2019
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancers Monoclonal Antibody Monoclonal Antibodies Lymphoma Oncogenes Protein Kinase Kras Humanized Antibody Ras Subfamily Bruton's Tyrosine Kinase Recombination Rp1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 388.97 |
| 52 Week Low | 204.17 |
| Average Volume | 166,610 |
| 200-Day Moving Average | 313.64 |
| 50-Day Moving Average | 337.61 |
| 20-Day Moving Average | 331.71 |
| 10-Day Moving Average | 323.56 |
| Average True Range | 12.30 |
| ADX | 20.85 |
| +DI | 14.17 |
| -DI | 27.22 |
| Chandelier Exit (Long, 3 ATRs) | 330.89 |
| Chandelier Exit (Short, 3 ATRs) | 341.08 |
| Upper Bollinger Bands | 362.18 |
| Lower Bollinger Band | 301.24 |
| Percent B (%b) | 0.26 |
| BandWidth | 18.37 |
| MACD Line | -6.04 |
| MACD Signal Line | -4.45 |
| MACD Histogram | -1.5987 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 331.21 | ||||
| Resistance 3 (R3) | 330.29 | 324.60 | 328.83 | ||
| Resistance 2 (R2) | 324.60 | 320.96 | 325.06 | 328.04 | |
| Resistance 1 (R1) | 320.77 | 318.72 | 322.68 | 321.69 | 327.24 |
| Pivot Point | 315.08 | 315.08 | 316.04 | 315.54 | 315.08 |
| Support 1 (S1) | 311.25 | 311.44 | 313.16 | 312.17 | 306.62 |
| Support 2 (S2) | 305.56 | 309.20 | 306.02 | 305.82 | |
| Support 3 (S3) | 301.73 | 305.56 | 305.03 | ||
| Support 4 (S4) | 302.65 |
